Our Partners

Idera compounds targeted to TLRs have broad potential applications in infectious diseases, autoimmune diseases, oncology, and asthma/allergies, and as vaccine adjuvants. To develop the potential of our discoveries in multiple areas simultaneously, we seek to advance certain applications through collaborations with pharmaceutical companies.

We currently have collaborative relationships for application of our technology in three therapeutic areas. We believe that our collaborations with Merck KGaA for cancer treatment, Merck & Co. for vaccines, and Novartis for asthma/allergies provide the necessary resources and expertise to advance these complex research programs. These collaborations have also brought us upfront payments that have helped to finance our internal pipeline. These collaborations could also result in additional payments if agreed upon milestones are achieved. We may also receive royalties if any commercial products result from our collaborations.

To obtain additional development resources and expertise, we may seek additional collaborations.